Delivery Order SPE2DB22D3301-SPE2DB25FY5YC

Award Date 6/9/25
Potential Completion Date 6/10/25
Potential Value $7.1K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of DUPIXENT 300 MG/2 ML PEN 2ML, with a ceiling value of $10,256.76 and a completion date of June 5, 2025. The contract is a firm fixed-price delivery order, with no set-aside designation, indicating open competition. Amerisourcebergen Drug Corp holds a significant...
This is a federal delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of DUPIXENT 300 MG/2 ML PEN 2ML, a pharmaceutical product, with a ceiling value of $11,667.51 and a period of performance through June 12, 2025. The contract is a firm-fixed-price delivery order, without a set-aside designation, indicating open competition. Amerisourcebergen Drug...
This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of DUPIXENT 300 MG/2 ML PEN 2ML, a pharmaceutical product, with a ceiling value of $11,908.02 and a performance period through May 22, 2025. The contract is firm fixed price and is not set aside for any specific business type. Amerisourcebergen Drug Corp holds a significant...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of DUPIXENT 300 MG/2 ML PEN 2ML, with a ceiling value of $11,130.04 and a period of performance through June 4, 2025. The contract is not set-aside and was competitively awarded. AmerisourceBergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with...
This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of DUPIXENT 300 MG/2 ML PEN 2ML, with a ceiling value of $53,889.41 and a performance period ending on May 16, 2025. The contract is a firm fixed-price delivery order, with no set-aside designation. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the supply of DUPIXENT 300 MG/2 ML PEN 2ML. The contract has a ceiling value of $2,090.75 and a completion date of May 15, 2025. The contract is a firm fixed price delivery order, with no set-aside designation, indicating open competition. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of DUPIXENT 300 MG/2 ML PEN 2ML, a pharmaceutical product, with a ceiling value of $7,443.78. The contract is a Firm Fixed Price type, with a completion date of June 9, 2025. This award is not set aside and was competed openly. Amerisourcebergen Drug Corp holds a significant Indefinite...
This is a federal delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $8,145.12 firm fixed-price delivery order is for DUPIXENT 300 MG/2 ML PEN 2ML, a medication, with a completion date of June 12, 2025. The contract has no set-aside designation, indicating open competition. Amerisourcebergen Drug Corp holds a significant $999,999,999.00 Indefinite Delivery Contract (IDC) with DLA...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of DUPIXENT 300 MG/2 ML PEN 2ML, a medication, with a ceiling value of $74,631.12 and a performance period ending on May 29, 2025. The contract is a firm-fixed-price delivery order and is not set aside for any particular business type. Amerisourcebergen Drug Corp also holds a significant...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the provision of DUPIXENT 300 MG/2 ML PEN 2ML. The contract is a firm-fixed-price delivery order with a ceiling value of $17,310.11 and a period of performance through May 27, 2025. This award is not set-aside and was competitively awarded. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support...
  • SPE2DB22D3301
    Indefinite Delivery Contract
  • SPE2DB22D3301-SPE2DB25FY5YC
    Delivery Order

This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of DUPIXENT 300 MG/2 ML PEN 2ML, with a ceiling value of $7,097.39 and a completion date of June 10, 2025. The contract is a firm fixed-price, non-set-aside award.

Amerisourcebergen Drug Corp holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999.00, which provides a comprehensive global pharmaceutical support vehicle with a performance period extending through December 2026. This IDC enables the company to supply a wide range of pharmaceutical products and medical supplies to support military healthcare programs worldwide, serving customers including the Defense Health Agency and the U.S. Coast Guard.

Generated 9/14/25, 12:48 AM